Taiwan Nucleic Acid and Gene Therapy Companies
As of October 22, 2026, this table includes nucleic acid or gene-therapy programs at 3 Taiwan companies. [1] [2] [3]
SNS812 has completed Phase 2, while the BIONET siRNA scar-prevention program and Excelsior EX-054 gene therapy are listed as preclinical. [1] [2] [3]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| Oneness Biotech Company source | 4743 | SNS812 (siRNA) | Coronavirus infection | Phase 2 complete; final clinical study report obtained | 2026-10-22 Stage source 完成二期臨床試驗，並取得最終臨床研究報告 | — |
| BIONET Therapeutics Company source | 7808 | siRNA scar-prevention program (individual drug code undisclosed) | Scar prevention | Preclinical | 2026-10-22 Stage source siRNA | — |
| Excelsior Biopharma Company source | 6496 | EX-054 (gene therapy) | Organic acidemia | Preclinical | 2025-12-16 Stage source EX-054 有機酸血症(基因治療) | — |
Scope and public-document limits
This is a source-verified selection rather than an industry census. Stages retain their individual source dates; undisclosed names, indications and event dates are not filled in.